Belite Bio Inc Adr (BLTE)

Mar 28, 2025

Belite Bio, Inc. Appoints New Auditor - TipRanks

Mar 28, 2025

Mar 28, 2025

Benchmark Reiterates Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World

Mar 28, 2025

Mar 26, 2025

Belite Bio stock target raised to $80 at Benchmark By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Belite Bio price target raised to $80 from $79 at Benchmark - TipRanks

Mar 26, 2025

Mar 26, 2025

Belite Bio stock target raised to $80 at Benchmark - Investing.com

Mar 26, 2025

Mar 24, 2025

Belite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating - TipRanks

Mar 24, 2025

Mar 21, 2025

Cantor Fitzgerald Forecasts Weaker Earnings for Belite Bio - Defense World

Mar 21, 2025

Mar 21, 2025

Belite Bio, Inc (NASDAQ:BLTE) Short Interest Up 17.1% in February - Defense World

Mar 21, 2025

Mar 21, 2025

HC Wainwright Has Pessimistic View of Belite Bio Q1 Earnings - Defense World

Mar 21, 2025

Mar 19, 2025

Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - Defense World

Mar 19, 2025

Mar 19, 2025

Belite Bio’s (BLTE) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World

Mar 19, 2025

Mar 18, 2025

Belite Bio’s Earnings Call: Cautious Optimism Amid Progress - TipRanks

Mar 18, 2025

Mar 18, 2025

Belite Bio Announces 2025 Annual Shareholder Meeting - TipRanks

Mar 18, 2025

Mar 18, 2025

Belite Bio stock holds $100 target post-results - Investing.com India

Mar 18, 2025

Mar 18, 2025

Positive Buy Rating for Belite Bio, Inc. Driven by Promising Phase 3 DRAGON Trial Results and Regulatory Prospects - TipRanks

Mar 18, 2025

Mar 18, 2025

Belite Bio (NASDAQ:BLTE) Shares Gap Down After Earnings Miss - Defense World

Mar 18, 2025

Mar 18, 2025

Belite Bio Advances in Retinal Disease Trials and Financial Position - TipRanks

Mar 18, 2025

Mar 17, 2025

Earnings call transcript: Belite Bio ADR Q4 2024 sees steady R&D progress - Investing.com Australia

Mar 17, 2025

Mar 17, 2025

Belite Bio reports Q4 EPS (32c), consensus (31c) - TipRanks

Mar 17, 2025

Mar 17, 2025

Belite Bio Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 17, 2025

Mar 17, 2025

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - Markets Insider

Mar 17, 2025

Mar 17, 2025

Belite Bio Releases 2024 Annual Report on Website - TipRanks

Mar 17, 2025

Mar 17, 2025

Belite Bio Reports Positive Interim Analysis Results for Phase 3 DRAGON Trial and Financial Update for Q4 2024 - Nasdaq

Mar 17, 2025

Mar 17, 2025

Public market insider buying at Savaria (SIS) - The Globe and Mail

Mar 17, 2025

Mar 17, 2025

Belite Bio's $145M War Chest Powers Critical Phase 3 Eye Disease Trial - StockTitan

Mar 17, 2025

Mar 16, 2025

Belite Bio (NASDAQ:BLTE) Trading Down 1.6% – Time to Sell? - Defense World

Mar 16, 2025

Mar 12, 2025

Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail

Mar 12, 2025

Mar 11, 2025

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 ... - The Bakersfield Californian

Mar 11, 2025

Mar 11, 2025

Biotech Pioneer Belite Bio Unveils Q4 and 2024 Performance: Key Retinal Disease Updates Coming March 17 - StockTitan

Mar 11, 2025

Mar 07, 2025

Is Meta Platforms Stock a Buy, Sell, or Hold Ahead of Llama 4 Launch? - The Globe and Mail

Mar 07, 2025

Mar 05, 2025

Parkland Reports Fourth Quarter and Year-End 2024 Results; Initiates Review of Strategic Alternatives - The Globe and Mail

Mar 05, 2025

Mar 04, 2025

Darwin CX Expands Internationally, Aiming to Tackle Global Publishing Challenges with Locally Tailored Solutions - The Globe and Mail

Mar 04, 2025

Mar 04, 2025

Can Belite Bio's Retinal Disease Treatments Impress Investors at Upcoming Leerink Conference? - StockTitan

Mar 04, 2025

Mar 03, 2025

2 Large-Cap Stocks with Exciting Potential and 1 to Avoid - The Globe and Mail

Mar 03, 2025

Feb 28, 2025

Belite Bio (NASDAQ:BLTE) Shares Gap UpShould You Buy? - MarketBeat

Feb 28, 2025

Feb 28, 2025

Promising Phase 3 Results for Belite Bio’s Tinlarebant in Stargardt Disease Boost Buy Rating - TipRanks

Feb 28, 2025

Feb 27, 2025

Belite Bio’s Phase 3 Trial for Stargardt Disease Drug Advances - TipRanks

Feb 27, 2025

Feb 27, 2025

Belite Bio Announces Interim Analysis Results from the - GlobeNewswire

Feb 27, 2025

Feb 27, 2025

Can Belite Bio's Tinlarebant Become First Treatment for Stargardt Disease? Phase 3 Data Shows Promise - StockTitan

Feb 27, 2025

Feb 25, 2025

Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat

Feb 25, 2025

Feb 23, 2025

Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume – Still a Buy? - The AM Reporter

Feb 23, 2025

Feb 20, 2025

Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.2% in January - MarketBeat

Feb 20, 2025

Feb 16, 2025

Belite Bio (NASDAQ:BLTE) Stock Price Up 7.8%Should You Buy? - MarketBeat

Feb 16, 2025

Feb 14, 2025

Belite Bio (NASDAQ:BLTE) Shares Down 4.7%Time to Sell? - MarketBeat

Feb 14, 2025

Feb 10, 2025

Advisors Preferred LLC Purchases New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Armenian Reporter

Feb 10, 2025

Feb 06, 2025

Belite Bio Announces $15 Million Direct Offering to Enhance Financial Position - TipRanks

Feb 06, 2025

Feb 06, 2025

BLTEBelite Bio, Inc Latest Stock News & Market Updates - StockTitan

Feb 06, 2025

Feb 05, 2025

Sangoma Announces Second Quarter Fiscal 2025 Results - The Globe and Mail

Feb 05, 2025

Feb 05, 2025

Why Oklo Stock Jumped 96% in January - The Globe and Mail

Feb 05, 2025